28 March 2025 | ReNerve Limited (ASX: RNV) (“ReNerve” or “the Company”), a medical device company focused on innovative products aimed at nerve repair and regeneration, is pleased to announce positive clinical data demonstrating the significant benefits of using the Company’s NervAlign® Nerve Cuff in peripheral nerve repair surgery.
The study results, presented this week at the American College of Foot and Ankle Surgeons (ACFAS 2025) Annual Conference in Arizona, show that patients who underwent nerve repair surgery using the NervAlign® Nerve Cuff experienced a statistically significant reduction in post-surgical pain and greater patient satisfaction compared to those who underwent surgery without the Nerve Cuff.
Highlights
-
Pain scores decreased from a pre-operative average of 7.1 to 0.4 in patients treated with the NervAlign® Nerve Cuff, compared to a reduction from 7.1 to 3.3 in patients treated without the Nerve Cuff.
-
93% of patients treated with the Nerve Cuff indicated they would elect to have the surgery again, compared to 70% in the non-cuff group.
-
The study demonstrated that the NervAlign® Nerve Cuff provides meaningful protection during nerve healing, leading to better long-term outcomes.
Commenting on the study, ReNerve CEO, Dr Julian Chick, stated: “These are very significant results for the development of ReNerve’s products, as they highlight the utility of the NervAlign® Nerve Cuff in reducing patients’ pain following peripheral nerve surgery. The results clearly demonstrate the patient benefits that follow from the proper repair and regeneration of a nerve that is returned to normal function post-surgery. The NervAlign® Nerve Cuff facilitates the patient's repair process is protected during the initial post-operative recovery and regeneration period. Thereafter, because the Nerve Cuff is absorbed naturally after six months, there is no longer a lasting 'foreign body' at the site of repair to create potential complications for the patient."
Study Design
-
Sample Size: 13 patients with the Nerve Cuff, 10 without
-
Gender: 21 Female, 2 Male
-
Average Age: 53
-
Average Follow-Up: 9.25 months
-
Endpoint Measures:
-
Visual Analogue Scale (VAS) for pain pre- and post-surgery
-
Willingness to repeat surgery as a proxy for patient satisfaction
-
About the NervAlign® Nerve Cuff
The NervAlign® Nerve Cuff is a bioabsorbable medical device designed to protect repaired nerves during the healing process following peripheral nerve surgery. It is absorbed naturally within six months, leaving no foreign material behind, and is suitable for use across a wide range of surgical procedures.
The study results further validate NervAlign® as a clinically meaningful innovation in nerve repair, with the potential to become a standard-of-care option for improving surgical outcomes and reducing patient discomfort post-operatively.
Dr Julian Chick
CEO & Managing Director
ReNerve Limited
[email protected]
Jane Morgan
Investor & Media Relations
Jane Morgan Management
[email protected]
About us:
About ReNerve Limited
ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry’s Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff™.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]